- Home
- DAN vs CNTA Comparison
DAN vs CNTA Comparison
Compare DAN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAN | CNTA |
|---|---|---|
| Founded | 1904 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DAN | CNTA |
|---|---|---|
| Price | $31.21 | $26.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $35.00 | ★ $40.89 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 04-29-2026 | 03-27-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 264.10 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $7,500,000,000.00 | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $49.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.11 | $9.60 |
| 52 Week High | $36.28 | $30.58 |
Technical Indicators
Market Signals| Indicator | DAN | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 51.06 |
| Support Level | $28.30 | $24.62 |
| Resistance Level | $31.73 | $27.56 |
| Average True Range (ATR) | 1.20 | 1.37 |
| MACD | -0.37 | 0.02 |
| Stochastic Oscillator | 7.99 | 43.26 |
Price Performance
Historical ComparisonAbout DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.